Achieve FY24 profit & PNV demonstrates (again) the growth trajectory and bottom line mgt, as per comments by TheAnalyst007. Other than that it’s meaningless to many LT holders..I mean if there wasn’t further innovation to be commercialised, I may not even be invested..Eg. DW says last month, the next big thing” will be DFUs”…. So perhaps the stalled Synpath trial to “confirm/amend study protocols” will align their marketing strategy for commercial release. This could be in consultation with a partner, in which case the trial itself could be more timed appropriately after we’ve hit the market.
PNV - Banter and General Comments, page-10380
-
- There are more pages in this discussion • 2,006 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.64 |
Change
-0.010(0.38%) |
Mkt cap ! $1.823B | |||
| Open | High | Low | Value | Volume |
| $2.62 | $2.64 | $2.58 | $2.297M | 877.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2375 | $2.62 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.64 | 3584 | 1 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| PNV (ASX) Chart |